聚烯胺接种的药物释放潜力-阿萨姆博拉大米多糖化物接种共聚合物 (ABRS-g-PAM) 作为有效的受控释放聚合物
Neha Singh1, Itishree Jogamaya Das1, Sutapa Satpathi1
1Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi, 835215, Jharkhand, India.
Carbohydrate research
|December 25, 2024
概括
这项研究优化了一种新型聚合物,阿萨姆博拉大米粉移植聚烯胺 (ABRS-g-PAM),用于控制药物输送. 最好的配方 (GF4) 显示出卓越的罗斯瓦斯塔丁释放和生物降解性.
科学领域:
- 聚合物化学 聚合物化学
- 材料科学 材料科学 材料科学
- 生物相容的聚合物
背景情况:
- 传统的药物输送系统经常面临控制释放和生物相容性方面的挑战.
- 从阿萨姆博拉大米粉 (ABRS) 等自然来源开发新的移植共聚合物为先进的药物输送应用提供了一个有前途的途径.
研究的目的:
- 为了合成和表征微波辅助聚烯胺移植阿萨姆博拉大米粉 (ABRS-g-PAM) 移植共聚合物.
- 优化移植共聚合物配方,以提高药物递送效率.
- 评估优化共聚合物的物理化学特性,胀行为,生物降解性和药物释放动力学.
主要方法:
- 微波辅助的ABRS-g-PAM移植共聚物的自由基合成.
- 优化接种效率 (% GE) 和内在粘度.
- 使用XRD,FTIR,TGA,DSC,13C NMR,SEM,FESEM和AFM进行表征.
- 在不同pH值和NaCl度下进行胀研究.
- 土壤生物降解性的评估.
- 在体外Rosuvastatin药物释放研究.
主要成果:
- 优化的ABRS-g-PAM等级配方4 (GF4) 在ABRS上表现出高效的聚烯胺接种.
- GF4表现出粗的表面形态和不规则的内部结构.
- 在pH 7和0.005M NaCl下观察到最大的胀,遵循二次动力学.
- 土壤的生物降解性证实了GF4的生物相容性.
- 在26小时内,GF4实现了99%的罗斯瓦斯塔丁释放,这表明控制释放特性.
结论:
- 优化的ABRS-g-PAM (GF4) 是一个有前途的生物相容材料,用于控制药物输送.
- 微波辅助合成为开发这种移植共聚合物提供了一种有效的方法.
- 该研究强调了ABRS-g-PAM作为可持续和有效的药物载体系统的潜力.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...